Archive | Webmaster | Accessibility | Conditions of use of web presentation | Privacy Policy | Site

Committee for Human Medicinal Products cobeca (CHMP) reviewed new data from studies that showed an increased risk of tumor progression, venous thromboembolism and shorter survival in patients with cancer treated with epoetin compared with the group without treatment with epoetin. The conclusion of the review showed that epoetins benefits outweigh the risks when used in the approved indications.
In patients with cancer, with an expected long-term survival, however, the use of epoetin benefit outweighs the risk of tumor progression and shorter overall survival at risk. Therefore, these patients should be treated with anemia blood transfusions.
For cancer patients with kidney disease are registered: Eprex (erythropoietin alfa), Aranesp and do not sleep (darbepoetin cobeca alfa), NeoRecormon (epoetin beta), and Silapo Retacrit (epoetin zeta), Abseamed, Binocrit, Epoetin Alfa Hexal (epoetin alfa) Only for patients with kidney disease are registered: Mircera (methoxypolyethylenglycol-epoetin beta) and Dynepo (epoetin delta)
Physicians are advised to base the decision to apply a medicine containing epoetin on an individual assessment of the benefit-risk ratio for the patient. Account should be taken of grading and staging of the tumor, the degree of anemia, the patient's life expectancy, the environment in which the patient is being treated, and patient preference.
Thank healthcare professionals for the reporting of suspected adverse cobeca drug reactions, which can be sent by post to the address SIDC, Šrobárova 48, Prague 10, 100 41, so e-mail to pharmacovigilance @ sukl com or fax to 272 185 816 It is also possible to use the electronic form for reporting adverse reactions, which is available on the website SIDC.
Calendar of events << >> November cobeca 2013 Mon Tue Wed Thu Fri Sat 1 2 3 4 5 6 7 8 9 10 Distributors - report distributed supply medicinal products (Note SIDC) 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Other activities Legislation and Guidelines Consultation SIDC administrative actions Publications International Activities External cooperation
Archive | Webmaster | Accessibility | Conditions of use of web presentation | Privacy Policy | Site visitors | Required Information | Contact Us | Site Map | Newsletter | RSS
Supplier portal QCM, sro